1Department of Korean Medicine, Wonkwang University, Iksan, Republic of Korea
2Usher Bio Co., Ltd., Incheon, Republic of Korea
3Department of Pharmacology, College of Korean Medicine, Pusan National University, Busan, Republic of Korea
4Kangchoo Korean Medicine Clinic, Incheon, Republic of Korea
5Mokpo Beautiful Care Hospital, Mokpo, Republic of Korea
6Department of Internal Medicine and Neuroscience, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea
7Department of Meridian and Acupoint, College of Korean Medicine, Wonkwang University, Iksan, Republic of Korea
8MapoHongik Korean Medicine Clinic, Seoul, Republic of Korea
©2025 Jaseng Medical Foundation
This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
Author Contributions
Conceptualization: HC, JEC, CL, and JC. Methodology: HC and JEC. Software: HC and JEC. Formal investigation: HC. Resources: HC. Data Analysis: HC and GRY. Writing of the Original Draft: HC, CL, and JC. Review and Editing: CL and JC.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Author Use of AI Tools Statement
The authors used ChatGPT (OpenAI) solely for grammar and language improvement during the revision of this manuscript. The AI tool did not contribute to the scientific content, data analysis, or interpretation. The authors take full responsibility for all content.
Funding
This research received support from a grant provided by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea (grant no.: HF20C0113).
Ethical Statement
Not applicable.
Authors, year, country, [reference] | Therapeutic effect | Group number (N, group) | Observation period | Route | Dose | Measured parameter and results (vs. control group) |
---|---|---|---|---|---|---|
Isohama et al, 2014, Japan [13] | Wound healing | 2, 8 | 7 d observation & treatment | Topical | Ointment containing 5 μg/site of STE. Treated once daily | ↓: Initial wound area |
Chen et al, 2017, Taiwan [14] | Antiviral (EV71) | 2, 15–16 | 14 d treatment, 17 d observation | Intraperitoneal | 250 mg/kg |
↑: Survival rate (87.5%) ↓: Severity & progression of neurologic symptoms |
Kim et al, 2016, Korea [15] | Anti-inflammatory/bone Health | 3, 5 | 8 d treatment & observation | LPS: Intraperitoneal | LPS (5 mg/kg) |
↑: BV/TV (15%), Tb.N (20%) ↓: Tb.Sp (15%), TRAP-positive osteoclasts |
Zhang et al, 2020, Korea [17] | Atopic dermatitis | 6, 8 | 5 wks | Topical application on dorsal skin | 200 μL of 30% STB, 30% AOM, or mix, in BG; applied twice daily | ↓: Skin thickness, Mast cell, Serum IgE, cytokines |
Choi et al, 2012, Korea [18] | Atopic dermatitis | 3, 5 | 17 d | Intraperitoneal | 250 mg/kg |
↓: Epidermal thickness (38.15%) IgE serum level (46.25%), TNF-α (41.97%), IL-6 (70.42%) Protein expression of NF-κB and MAPKs (JNK, ERK, p38) |
Shin et al, 1999, Korea [19] | Anti-allergic/anaphylaxis | Multiple, at least 3 | 1 h for systemic anaphylaxis | Intraperitoneal | STAE 0.005 to 1 g/kg; compound 48/80 | ↓: Mortality rate, plasma histamine |
AD-Con = atopic dermatitis control group; AOM = alpiniae oxyphyllae fructus; BG = 1,3-butylene glycol; BV/TV = bone volume/tissue volume; ERK = extracellular signal-regulated kinases; IgE = immunoglobulin E; IL-6 = interleukin-6; JNK = c-Jun N-terminal kinases; LPS = lipopolysaccharide; MAPKs = mitogen-activated protein kinases; NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells; p38 = p38 mitogen-activated protein kinases; STAE = Schizonepeta tenuifolia aqueous extract; STE = Schizonepeta tenuifolia extract; STB = Schizonepeta tenuifolia Briq; Tb.N = trabecular number; Tb.Sp = trabecular separation; TNF-α = tumor necrosis factor-alpha; TRAP = tartrate-resistant acid phosphatase.
Authors, year, country, [reference] | Therapeutic effect/key Finding | Extraction method/solvent | Assay type/treatment conditions | Key results (quantitative/qualitative) |
---|---|---|---|---|
Kang et al, 2010, Korea [20] | Immunomodulatory/anti-inflammatory | Distilled water | Splenocytes /PBMCs + anti-CD3± STE/DEX; Splenocytes + anti-CD3/IL-12 +STE/CsA /DE |
No cytotoxicity (up to 100 μg/mL) ↑: Mitogenic activity (Splenocytes) (1.5–2.5 fold), IL-2 transcription, IFN-γ transcription (8 h, 24 h), IL-2 (Splenocytes /PBMCs), NFATc2 nuclear translocation, STAT4 phosphorylation, STAT6 phosphorylation ↓: IFN-γ transcription (at 48 h), IL-4 transcription, IFN-γ & IL-4 (splenocytes /PBMCs), p65 nuclear translocation |
Kang et al, 2010, Korea [21] | Anti-inflammatory | Distilled water | Macrophages + LPS ± STE (50–200 μg/mL) / DE |
No cytotoxicity (up to 400 μg/mL) ↓: TNF-α (6 h, 24 h), IL-6 (6 h), TNF-α mRNA (4 h), IkBα degradation (15 min), p65 nuclear translocation, JNK/SAPK phosphorylation, c-Jun phosphorylation, ATF-2 phosphorylation |
Sohn et al, 2012, Korea [22] | Anti-inflammatory/gene regulation | Unidentified | HMC-1 + PMA/A23187 ± ST/chemicals |
No cytotoxic effect (STE only) ↑: Viability (HMC-1 stimulated) (specific chemicals) ↓: TNF-α, IL-6, IL-8 (specific chemicals), specific gene expression (8 genes) |
Byun et al, 2014, Korea [23] | Anti-inflammatory | 70% ethanol | BMDMs + LPS ± STE (25–100 μg/mL |
Cell viability: maintained (up to 100μg/mL, 24h) ↓: NO, iNOS, COX-2, PGE2, IL-1β, IL-6, CD80, CD86, TNF-α, TLR4 protein, p38 phosphorylation, ERK1/2 phosphorylation, IkB-α phosphorylation, p65 nuclear translocation |
Isohama et al, 2014, Japan [13] | Skin barrier function/wound healing | Methanol | DJM-1 ± TNF-α +STE/DEX; Scratched DJM-1 + STE ± AQP3 siRNA |
↓: AQP3 mRNA & protein (TNF-α treated), water permeability ↑: AQP3 mRNA (STE only) (up to 2.5-fold), AQP3 protein (STE only), AQP3 mRNA (TNF-α + STE), gap closure/migration (effect abolished by AQP3 siRNA) |
Ng et al, 2018, Korea [24] | Antiviral (norovirus) | 80% methanol | HG23 (replicon) ± STE/RBV /LGEO/chemicals; RAW + MNV-1 ± STE/RB |
No cytotoxicity (HG23 cells) ↓: Viral RNA (HG23), MNV-1 plaque formation, MNV-1 RNA levels ↑: IFN-β mRNA (HG23), IFN-γ mRNA (HG23), mIFN-β mRNA (RAW 264.7), IRF3 phosphorylation (RAW 264.7) |
Jeon et al, 2019, Korea [25] | Anti-platelet aggregation | Methanol | Washed platelets + collagen/ADP/thrombin ± STE (vehicle control) |
↓: Collagen-induced platelet aggregation, [Ca2+]i, ATP secretion, fibrinogen binding to integrin αIIbβ3, Phosphorylation (ERK, JNK, MEK, Akt) No effect: ADP-induced aggregation |
Chen et al, 2017, Taiwan [14] | Antiviral (EV71) | Distilled water | RD/Vero cells + EV71 ± STE; + p38 MAPK Inhibitor (SB202190); +H2O2; Transfection | ↓: EV71 plaque formation, RNA replication, Protein synthesis, Viral particle production, IRES-dependent translation, eIF4G cleavage, hnRNP A1 cytoplasmic translocation, p38 MAPK activation, EPS15 phosphorylation, EV71-induced ROS generation |
Kim et al, 2016, Korea [15] | Anti-osteoclastogenesis/bone health | 95% ethanol | BMMs + M-CSF + RANKL ± EEST; retroviral transfection |
No cytotoxicity ↓: RANKL-induced osteoclast formation, Akt phosphorylation, IkB phosphorylation, c-Fos expression, NFATc1 expression, F-actin ring formation, bone resorption activity, osteoclast-specific gene expression (multiple genes) |
Liu et al, 2021, China [16] | Anti-inflammatory/antiviral (RSV) | 75% ethanol (v/v) for SS and SSC | RAW 264.7 + LPS ± SS/SSC; HEp-2 + RSV ± SS/SSC; chem. profile |
↓: Anti-inflammatory effect (SSC vs SS), essential oil yield (SSC vs SS) (91%) ↑: Antiviral activity (SSC vs SS) Altered: chemical profile (charred vs raw) |
Shin et al, 1999, Korea [19] | Anti-allergic/mast cell degranulation | Distilled water | Mast cells + Cpd 48/80 or anti-DNP IgE + DNP-HAS ± STA |
↓: Histamine release ↑: TNF-α production |
BMDMs = bone marrow-derived macrophages; bSS = β-Sitosterol; [Ca2+]i = intracellular calcium level; CO = caryophyllene oxide; COX-2 = cyclooxygenase-2; CPE = cytopathic effect; CsA = cyclosporine A; eIF4G = eukaryotic initiation factor 4G; EEST = ethanol extract of Schizonepeta tenuifolia; EPS15 = epidermal growth factor receptor pathway substrate 15; EV71 = Enterovirus 71; HG23 = human astrocytoma U-87 MG cells (infected with human enterovirus 71, strain HG23); hnRNP A1 = heterogeneous nuclear ribonucleoprotein A1; HP = hesperidin; IκB-α = inhibitor of kappa B alpha; IC50 = half-maximal inhibitory concentration; IFN-β = interferon-beta; IFN-γ = interferon-gamma; IL-1β = interleukin-1 beta; IL-2 = interleukin-2; IL-4 = interleukin-4; IL-8 = interleukin-8; iNOS = inducible nitric oxide synthase; IRES = internal ribosomal entry site; IRF3 = interferon regulatory factor 3; LEGO = Lonicera japonica-Erigeron annuus-Gleditsia sinensis extract; LG = luteolin-7-O-glucuroninide; MAPK = mitogen-activated protein kinases; MEK = mitogen-activated protein kinase kinase; mIFN-β = murine IFN-β; MNV-1 = murine norovirus 1; MTS assay = 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay; NFATc2 = nuclear factor of activated T-cells, cytoplasmic 2; NO = nitric oxide; PBMCs = peripheral blood mononuclear cells; PG = pulegone; PGE2 = prostaglandin E2; PI3K = phosphoinositide 3-kinase; pma = phorbol 12-myristate 13-acetate; (+)-M = (+)-Menthone; (−)-P = (S)-(−)-Pulegone; RA = rosmarinic acid; RANKL = receptor activator of nuclear factor kappa-B ligand; RBV = ribavirin; ROS = reactive oxygen species; RSV = respiratory syncytial virus; RT-qPCR = reverse transcription quantitative polymerase chain reaction; SI = selectivity index; SS = Schizonepeta tenuifolia raw; SSC = Schizonepeta tenuifolia charred; STAT4 = signal transducer and activator of transcription 4; STAT6 = signal transducer and activator of transcription 6; TH = 2α,3α,24-trihydroxyolean-12en-28oic acid; TLR4 = toll-like receptor 4; UA = ursolic acid; VP1 = viral protein 1; XTT assay = 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay.
Authors, year, country, [reference] | Therapeutic effect | Group number (N, group) | Observation period | Route | Dose | Measured parameter and results (vs. control group) |
---|---|---|---|---|---|---|
Isohama et al, 2014, Japan [ |
Wound healing | 2, 8 | 7 d observation & treatment | Topical | Ointment containing 5 μg/site of STE. Treated once daily | ↓: Initial wound area |
Chen et al, 2017, Taiwan [ |
Antiviral (EV71) | 2, 15–16 | 14 d treatment, 17 d observation | Intraperitoneal | 250 mg/kg | ↑: Survival rate (87.5%) ↓: Severity & progression of neurologic symptoms |
Kim et al, 2016, Korea [ |
Anti-inflammatory/bone Health | 3, 5 | 8 d treatment & observation | LPS: Intraperitoneal | LPS (5 mg/kg) | ↑: BV/TV (15%), Tb.N (20%) ↓: Tb.Sp (15%), TRAP-positive osteoclasts |
Zhang et al, 2020, Korea [ |
Atopic dermatitis | 6, 8 | 5 wks | Topical application on dorsal skin | 200 μL of 30% STB, 30% AOM, or mix, in BG; applied twice daily | ↓: Skin thickness, Mast cell, Serum IgE, cytokines |
Choi et al, 2012, Korea [ |
Atopic dermatitis | 3, 5 | 17 d | Intraperitoneal | 250 mg/kg | ↓: Epidermal thickness (38.15%) IgE serum level (46.25%), TNF-α (41.97%), IL-6 (70.42%) Protein expression of NF-κB and MAPKs (JNK, ERK, p38) |
Shin et al, 1999, Korea [ |
Anti-allergic/anaphylaxis | Multiple, at least 3 | 1 h for systemic anaphylaxis | Intraperitoneal | STAE 0.005 to 1 g/kg; compound 48/80 | ↓: Mortality rate, plasma histamine |
Authors, year, country, [reference] | Therapeutic effect/key Finding | Extraction method/solvent | Assay type/treatment conditions | Key results (quantitative/qualitative) |
---|---|---|---|---|
Kang et al, 2010, Korea [ |
Immunomodulatory/anti-inflammatory | Distilled water | Splenocytes /PBMCs + anti-CD3± STE/DEX; Splenocytes + anti-CD3/IL-12 +STE/CsA /DE | No cytotoxicity (up to 100 μg/mL) ↑: Mitogenic activity (Splenocytes) (1.5–2.5 fold), IL-2 transcription, IFN-γ transcription (8 h, 24 h), IL-2 (Splenocytes /PBMCs), NFATc2 nuclear translocation, STAT4 phosphorylation, STAT6 phosphorylation ↓: IFN-γ transcription (at 48 h), IL-4 transcription, IFN-γ & IL-4 (splenocytes /PBMCs), p65 nuclear translocation |
Kang et al, 2010, Korea [ |
Anti-inflammatory | Distilled water | Macrophages + LPS ± STE (50–200 μg/mL) / DE | No cytotoxicity (up to 400 μg/mL) ↓: TNF-α (6 h, 24 h), IL-6 (6 h), TNF-α mRNA (4 h), IkBα degradation (15 min), p65 nuclear translocation, JNK/SAPK phosphorylation, c-Jun phosphorylation, ATF-2 phosphorylation |
Sohn et al, 2012, Korea [ |
Anti-inflammatory/gene regulation | Unidentified | HMC-1 + PMA/A23187 ± ST/chemicals | No cytotoxic effect (STE only) ↑: Viability (HMC-1 stimulated) (specific chemicals) ↓: TNF-α, IL-6, IL-8 (specific chemicals), specific gene expression (8 genes) |
Byun et al, 2014, Korea [ |
Anti-inflammatory | 70% ethanol | BMDMs + LPS ± STE (25–100 μg/mL | Cell viability: maintained (up to 100μg/mL, 24h) ↓: NO, iNOS, COX-2, PGE2, IL-1β, IL-6, CD80, CD86, TNF-α, TLR4 protein, p38 phosphorylation, ERK1/2 phosphorylation, IkB-α phosphorylation, p65 nuclear translocation |
Isohama et al, 2014, Japan [ |
Skin barrier function/wound healing | Methanol | DJM-1 ± TNF-α +STE/DEX; Scratched DJM-1 + STE ± AQP3 siRNA | ↓: AQP3 mRNA & protein (TNF-α treated), water permeability ↑: AQP3 mRNA (STE only) (up to 2.5-fold), AQP3 protein (STE only), AQP3 mRNA (TNF-α + STE), gap closure/migration (effect abolished by AQP3 siRNA) |
Ng et al, 2018, Korea [ |
Antiviral (norovirus) | 80% methanol | HG23 (replicon) ± STE/RBV /LGEO/chemicals; RAW + MNV-1 ± STE/RB | No cytotoxicity (HG23 cells) ↓: Viral RNA (HG23), MNV-1 plaque formation, MNV-1 RNA levels ↑: IFN-β mRNA (HG23), IFN-γ mRNA (HG23), mIFN-β mRNA (RAW 264.7), IRF3 phosphorylation (RAW 264.7) |
Jeon et al, 2019, Korea [ |
Anti-platelet aggregation | Methanol | Washed platelets + collagen/ADP/thrombin ± STE (vehicle control) | ↓: Collagen-induced platelet aggregation, [Ca2+]i, ATP secretion, fibrinogen binding to integrin αIIbβ3, Phosphorylation (ERK, JNK, MEK, Akt) No effect: ADP-induced aggregation |
Chen et al, 2017, Taiwan [ |
Antiviral (EV71) | Distilled water | RD/Vero cells + EV71 ± STE; + p38 MAPK Inhibitor (SB202190); +H2O2; Transfection | ↓: EV71 plaque formation, RNA replication, Protein synthesis, Viral particle production, IRES-dependent translation, eIF4G cleavage, hnRNP A1 cytoplasmic translocation, p38 MAPK activation, EPS15 phosphorylation, EV71-induced ROS generation |
Kim et al, 2016, Korea [ |
Anti-osteoclastogenesis/bone health | 95% ethanol | BMMs + M-CSF + RANKL ± EEST; retroviral transfection | No cytotoxicity ↓: RANKL-induced osteoclast formation, Akt phosphorylation, IkB phosphorylation, c-Fos expression, NFATc1 expression, F-actin ring formation, bone resorption activity, osteoclast-specific gene expression (multiple genes) |
Liu et al, 2021, China [ |
Anti-inflammatory/antiviral (RSV) | 75% ethanol (v/v) for SS and SSC | RAW 264.7 + LPS ± SS/SSC; HEp-2 + RSV ± SS/SSC; chem. profile | ↓: Anti-inflammatory effect (SSC vs SS), essential oil yield (SSC vs SS) (91%) ↑: Antiviral activity (SSC vs SS) Altered: chemical profile (charred vs raw) |
Shin et al, 1999, Korea [ |
Anti-allergic/mast cell degranulation | Distilled water | Mast cells + Cpd 48/80 or anti-DNP IgE + DNP-HAS ± STA | ↓: Histamine release ↑: TNF-α production |
AD-Con = atopic dermatitis control group; AOM = alpiniae oxyphyllae fructus; BG = 1,3-butylene glycol; BV/TV = bone volume/tissue volume; ERK = extracellular signal-regulated kinases; IgE = immunoglobulin E; IL-6 = interleukin-6; JNK = c-Jun N-terminal kinases; LPS = lipopolysaccharide; MAPKs = mitogen-activated protein kinases; NF-κB = nuclear factor kappa-light-chain-enhancer of activated B cells; p38 = p38 mitogen-activated protein kinases; STAE = Schizonepeta tenuifolia aqueous extract; STE = Schizonepeta tenuifolia extract; STB = Schizonepeta tenuifolia Briq; Tb.N = trabecular number; Tb.Sp = trabecular separation; TNF-α = tumor necrosis factor-alpha; TRAP = tartrate-resistant acid phosphatase.
BMDMs = bone marrow-derived macrophages; bSS = β-Sitosterol; [Ca2+]i = intracellular calcium level; CO = caryophyllene oxide; COX-2 = cyclooxygenase-2; CPE = cytopathic effect; CsA = cyclosporine A; eIF4G = eukaryotic initiation factor 4G; EEST = ethanol extract of Schizonepeta tenuifolia; EPS15 = epidermal growth factor receptor pathway substrate 15; EV71 = Enterovirus 71; HG23 = human astrocytoma U-87 MG cells (infected with human enterovirus 71, strain HG23); hnRNP A1 = heterogeneous nuclear ribonucleoprotein A1; HP = hesperidin; IκB-α = inhibitor of kappa B alpha; IC50 = half-maximal inhibitory concentration; IFN-β = interferon-beta; IFN-γ = interferon-gamma; IL-1β = interleukin-1 beta; IL-2 = interleukin-2; IL-4 = interleukin-4; IL-8 = interleukin-8; iNOS = inducible nitric oxide synthase; IRES = internal ribosomal entry site; IRF3 = interferon regulatory factor 3; LEGO = Lonicera japonica-Erigeron annuus-Gleditsia sinensis extract; LG = luteolin-7-O-glucuroninide; MAPK = mitogen-activated protein kinases; MEK = mitogen-activated protein kinase kinase; mIFN-β = murine IFN-β; MNV-1 = murine norovirus 1; MTS assay = 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay; NFATc2 = nuclear factor of activated T-cells, cytoplasmic 2; NO = nitric oxide; PBMCs = peripheral blood mononuclear cells; PG = pulegone; PGE2 = prostaglandin E2; PI3K = phosphoinositide 3-kinase; pma = phorbol 12-myristate 13-acetate; (+)-M = (+)-Menthone; (−)-P = (S)-(−)-Pulegone; RA = rosmarinic acid; RANKL = receptor activator of nuclear factor kappa-B ligand; RBV = ribavirin; ROS = reactive oxygen species; RSV = respiratory syncytial virus; RT-qPCR = reverse transcription quantitative polymerase chain reaction; SI = selectivity index; SS = Schizonepeta tenuifolia raw; SSC = Schizonepeta tenuifolia charred; STAT4 = signal transducer and activator of transcription 4; STAT6 = signal transducer and activator of transcription 6; TH = 2α,3α,24-trihydroxyolean-12en-28oic acid; TLR4 = toll-like receptor 4; UA = ursolic acid; VP1 = viral protein 1; XTT assay = 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide assay.